Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
10.21
-0.08 (-0.78%)
At close: Aug 20, 2025, 4:00 PM
10.25
+0.04 (0.37%)
After-hours: Aug 20, 2025, 7:56 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 403 employees as of December 31, 2024. The number of employees decreased by 123 or -23.38% compared to the previous year.
Employees
403
Change (1Y)
-123
Growth (1Y)
-23.38%
Revenue / Employee
$131,159
Profits / Employee
-$1,191,548
Market Cap
1.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 403 | -123 | -23.38% |
Dec 31, 2023 | 526 | -72 | -12.04% |
Dec 31, 2022 | 598 | 113 | 23.30% |
Dec 31, 2021 | 485 | 173 | 55.45% |
Dec 31, 2020 | 312 | 42 | 15.56% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTLA News
- 5 days ago - Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) - Seeking Alpha
- 13 days ago - Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - GlobeNewsWire
- 21 days ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
- 4 weeks ago - With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy' - Seeking Alpha
- 2 months ago - Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewsWire
- 2 months ago - Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga